Covered recipient · General Payments record
JOANNA Y DU
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$3,323.14
- Reported across 140 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $521.68 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $156.24 | 1 |
| REVANCE THERAPEUTICS, INC. | $117.50 | 1 |
| Astellas Pharma US Inc | $65.66 | 3 |
| PFIZER INC. | $55.64 | 3 |
| MIMEDX Group, Inc. | $29.80 | 1 |
| Minerva Surgical, Inc | $26.79 | 1 |
| Aspira Women's Health Inc | $21.70 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $19.37 | 1 |
| Sumitomo Pharma America, Inc. | $18.69 | 1 |
| Meditrina | $10.29 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $156.24 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085231 | CMS |
| Aspira Women's Health Inc | $21.70 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126779290 | CMS |
| Astellas Pharma US Inc | $23.44 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139297100 | CMS |
| Astellas Pharma US Inc | $22.22 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139382494 | CMS |
| Astellas Pharma US Inc | $20.00 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139432530 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $19.37 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086250676 | CMS |
| Meditrina | $10.29 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154265976 | CMS |
| MIMEDX Group, Inc. | $29.80 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140258363 | CMS |
| Minerva Surgical, Inc | $26.79 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1085612223 | CMS |
| PFIZER INC. | $14.46 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131308899 | CMS |
| PFIZER INC. | $16.70 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131256867 | CMS |
| PFIZER INC. | $24.48 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131442380 | CMS |
| REVANCE THERAPEUTICS, INC. | $117.50 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147916799 | CMS |
| Sumitomo Pharma America, Inc. | $18.69 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148846877 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.